RX-10001
RX-10001 (RvE1): The resolvin, RX-10001, is a naturally occurring, small molecule lipid mediator. RX-10001 acts to protect healthy tissue during an inflammatory response to an environmental insult and to resolve inflammation once the environmental insult has passed. Pre-clinically, RX-10001 is active with very high potency across a range of inflammatory disease models, including asthma, colitis, rheumatoid arthritis, atherosclerosis, dry eye and retinopathy, and is active by oral, IV and subcutaneous routes of administration. As an active metabolite of the omega-3 fatty acid, EPA, RX-10001 may account for the proven health benefits of omega-3s and is anticipated to have an exceptional safety profile in the clinic. To prove concept, RX-10001 will be evaluated initially in an exercise-challenge asthma clinical trial and will subsequently be tested broadly across multiple inflammatory diseases.